AJANTPHARM2023-04-012023-06-30 AJANTPHARM2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2023-06-30 AJANTPHARM2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532331 AJANTPHARM NA Ajanta Pharma Limited Equity 2023-04-01 2024-03-31 2023-07-27 2023-07-14 INR Crores First quarter 14:00:00 15:40:00 2023-07-27 2023-07-27 Not applicable Single segment PHARMACEUTICAL 2023-04-01 2023-06-30 Unaudited Consolidated 10210400000.00 317500000.00 10527900000.00 2178100000.00 396400000.00 -55500000.00 2132100000.00 8500000.00 331800000.00 2846100000.00 7837500000.00 2690400000.00 0.00 2690400000.00 683200000.00 -74000000.00 609200000.00 0.00 2081200000.00 0.00 0.00 0.00 0.00 2081200000.00 -26400000.00 2054800000.00 0.00 0.00 0.00 0.00 252700000.00 2 16.53 16.53 0.00 0.00 16.53 16.53 1. The above consolidated financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 27 July 2023. The statutory auditors have expressed an unmodified opinion. The review report has been filed with the stock exchange and is available on company website. 2. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. 3. Board of Directors have approved 1st interim dividend of Rs. 315 Crore for the financial year 2023-24 to its shareholders @ Rs. 25 per share (1250%) on the face value of Rs. 2 per share. This total dividend includes regular dividend of Rs. 10 per share (500%) and an additional Rs. 15 per share (750%) distributed as a special dividend on the commemoration of 50 years of momentous journey of the Company. 4. Other income / Other expense includes : Rs. in crore 3 months ended Year ended 30-Jun-23 31-Mar-23 30-Jun-22 31-Mar-23 Foreign exchange gain 19.68 24.52 27.61 66.07 (in other income) Foreign exchange loss 9.99 21.71 2.45 18.82 (in other expenses) 5. The figures for the quarter ended 31 March 2023 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2022. 6. During the quarter 1,000 (previous year 1,000) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to Share Based Incentive Plan, 2019, resulting in an increase in paid-up share capital by Rs. 2,000 (previous year Rs. 2,000) and securities premium by Rs. 0.18 crores (previous year Rs. 0.18 crores). 7. On 10 March 2023, Company has announced buy back of its 22,10,500 equity shares, being 2.59% of the total paid up equity share capital at Rs. 1,425 per equity share for an aggregate amount of Rs. 315.00 crores. The buy back opened on 31 March 2023, closed on 10 April 2023 and Company extinguished those shares on 19 April 2023. 8. The Group operates exclusively in one reportable business segment i.e., Pharmaceuticals . 9. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com. Other Expenses 2846100000.00 Items that will not to be reclassified subsequently to profit or loss -9600000.00 -9600000.00 -3400000.00 Items that will be reclassified subsequently to profit or loss -20200000.00 -20200000.00 0.00